大黄蛰虫丸联合TACE术对原发性肝癌患者(瘀血阻络型)VEGF,MMP-2,TGF-β1及免疫功能的影响

Effect of Dahuang Zhechong Pills combined with TACE on VEGF,MMP-2,TGF-β1 and immune function of patients with primary liver cancer(blood stasis and collaterals blocking type)

探讨大黄蛰虫丸联合肝动脉化疗栓塞术(hepatic artery chemoembolization,TACE术)治疗对原发性肝癌患者(瘀血阻络型)肿瘤指标及免疫功能的影响,观察其在此类患者治疗中的应用价值,旨在为该病提供有效的治疗手段。将2019年6月至2019年12月因原发性肝癌患者(瘀血阻络型)于温州市中医院就诊的79例纳入研究,纳入研究前均用随机数字表法对患者进行分组。对照组40例患者单纯采用TACE术,观察组39例患者联合大黄蛰虫丸口服治疗,治疗4周后比较疗效。结果治疗后观察组血清CD4+细胞、CD4+/CD8+、CD3+细胞等免疫功能指标均大于对照组,差异有统计学意义(P<0.05);观察组血清甲胎蛋白(alpha-fetoprotein,AFP)、糖类抗原199(carbohydrate antigen 199,CA199)等肿瘤指标,谷丙转氨酶(glutamic-pyruvic transaminase,ALT)、总胆红素(total bilirubin,TBiL)水平低于对照组,差异有统计学意义(P<0.05);观察组血浆血管内皮生长因子(vascular endothelial growth factor,VEGF)、转化生长因子-β1(transforming growth factor-β1,TGF-β1)、基质金属蛋白酶-2(matrix metalloproteinase-2,MMP-2)水平低于对照组,差异有统计学意义(P<0.05);观察组总有效率87.18%,获益率94.87%,对照组总有效率67.50%,获益率85.00%,观察组总有效率高于对照组(P<0.05);观察组骨髓抑制、胃肠道反应、发热、肾功能损伤、周围神经损伤等不良反应总发生率48.72%,低于对照组的82.50%,差异有统计学意义(P<0.05)。结果表明,对于原发性肝癌患者(瘀血阻络型),采用大黄蛰虫丸联合TACE术治疗有重要意义,有助于提高免疫力,保护肝功能,降低转移风险,降低化疗不良反应发生,值得推广。

To investigate the effects of Dahuang Zhechong Pills combined with hepatic arterial chemoembolization(TACE)on tumor index and immune function of patients with primary liver cancer(blood stasis and collaterals blocking type),observe its application values in treatment of such patients,and provide effective treatment means for this disease.From June 2019 to December 2019,79 patients with confirmed primary liver cancer(blood stasis and collaterals blocking type)treated in Wenzhou Hospital of Traditional Chinese Medicine were included in this study,all of which were grouped with random number table method before inclusion in this study.40 patients in the control group were treated with TACE,while 39 patients in the observation group were treated with Dahuang Zhechong Pills combined with TACE.The efficacy was compared between two groups after 4 weeks of treatment.The immune function indexes of serum CD4+cells,CD4+/CD8+,CD3+cells of the observation group were higher than those in control group after treatment(P<0.05),and tumor indexes such as serum alpha-fetoprotein(AFP),carbohydrate antigen 199(CA199)and glutamic-pyruvic transaminase(ALT),total bilirubin(TBiL)levels were lower than those in the control group,with statistically significant differences(P<0.05).Plasma vascular endothelial growth factor(VEGF),transforming growth factor-β1(TGF-β1),and matrix metalloprotei-nase-2(MMP-2)levels in the observation group were lower than those in the control group after treatment,with statistically significant differences(P<0.05).The total effective rate of the observation group was 87.18%,higher than 67.50%in the control group,and the benefit rate was 94.87%in the observation group,higher than 85.00%in the control group(P<0.05).The total incidence of adverse reactions such as bone marrow suppression,gastrointestinal reaction,fever,renal function injury and peripheral nerve injury in the observation group was 48.72%,lower than 82.50%in the control group,with statistically significant difference(P<0.05).In summary,the combination of Dahuang Zhechong Pills with TACE could improve immunity,protect liver function,and reduce the risk of metastasis and the incidence of adverse reactions from chemotherapy,so it is worth popularizing for patients with primary liver cancer(blood stasis and collaterals blocking type).